InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,127.79
(
1.26%
)
US TECH 100
17,446.00
(
2.17%
)
Dow Jones
38,675.68
(
1.18%
)
Brent Oil
83.32
(
0.23%
)
Bitcoin
64,341.30
(
0.53%
)
Post# of 251721
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 826
Posts 119569
Boards Moderated 14
Alias Born 09/05/2002

DewDiligence

Member Level

Re: ThomasS post# 87794

Friday, 12/18/2009 5:39:58 PM

Friday, December 18, 2009 5:39:58 PM

Post# of 251721
MNTA: The potential milestones from NVS attributable to M178 comprised only 8% ($15M) of the $178M of potential milestones payable by NVS under the companies’ amended 2006 collaboration:

http://sec.gov/Archives/edgar/data/1235010/000110465909070614/a09-35662_18k.htm

Although today’s SEC filing says that some of the $15M attributable to M178 could still be received, I don’t think investors should count on it. Thus, the realistic milestone figure from the 2006 NVS collaboration is now $163M, which consists of milestones pertaining to Lovenox and Copaxone.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up